The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study.
Nadia N. Laack
Research Funding - Bristol-Myers Squibb
Evanthia Galanis
Research Funding - Bristol-Myers Squibb
Clinton Leinweber
No relevant relationships to disclose
Jan C. Buckner
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Francois J. Geoffroy
No relevant relationships to disclose
Kurt A. Jaeckle
No relevant relationships to disclose
Jann Nagina Sarkaria
No relevant relationships to disclose